Bristol Myers Squibb to Participate in the 2023 UBS BioPharma Conference

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the 2023 UBS BioPharma Conference in Miami Beach, Florida, on Wednesday, November 8, 2023. Lynelle Hoch, president, cell therapy organization, will answer questions about the company during a fireside chat at 8:00 a.m. ET.

Investors and the general public are invited to listen to a live webcast of the session here. An archived edition of the session will be available following its conclusion.

About Bristol Myers Squibb Company

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.

corporatefinancial-news

View source version on businesswire.com: https://www.businesswire.com/news/home/20231102123241/en/

For more information:

Media:
[email protected]

Investors:
[email protected]

Source: Bristol Myers Squibb

You May Also Be Interested In

• Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European
• HYPERLIQUID Draws Fresh Attention as IceBull Enters the Next Crypto to Explode Race With Stage 1 Still Live
• ABC Test Tag & Fire Formalizes Bundled Compliance Packages for SEQ